According to a new market research report "Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022", published by MarketsandMarkets™, the market is expected to reach USD 5.69 Billion by 2022 from USD 4.24 Billion in 2017, at a CAGR of 6.1%.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=47265247

The market is being driven by the growth in aging population and the associated increase in the prevalence of Parkinsons disease and government funding for research.

Asia to offer lucrative growth opportunities

By region, the global Parkinsons disease treatment market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). While Europe is expected to hold the largest share of the market in 2017, Asia is expected to grow at the highest CAGR during the forecast period. Increasing number of players in the region and the rising aging population are some major factors driving the high growth of this regional segment.

Key Market Players

Some of the major players operating in the Parkinsons disease treatment market include Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany),  Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).

Value Addition for the Buyer:

This report aims to provide insights into the global Parkinson’s disease treatment market. It provides valuable information on the market classification by drug class, distribution channels, and patient care setting. Details on regional markets for these segments have also been presented in this report. In addition, leading players in the market are profiled to understand the strategies undertaken by them to be competitive in this market.

This report categorizes the market into the following segments:

By Drug Class

• Levodopa/carbidopa
• Dopamine Receptor Agonists

MAO-Inhibitors

• COMT-inhibitors
• Anticholinergics
• Other Drugs

By Distribution Channel

• Hospital Pharmacies
• Retailer Pharmacies
• Online Pharmacies

By Patient Care Setting

• Hospitals
• Clinics

By Region

• North America
• Europe
• Asia
• Rest of the World (RoW)

Talk To Our Research Analysts: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=47265247